acipimox
Phase 2Small molecule
Boehringer Ingelheimacipimox is one of 140 small molecule programs targeting Prediabetes Syndrome. It is currently in Phase 2.
7
Indications
19
Total Trials
3
Active Trials
139
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
146 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Cardene
Sun Pharmaceutical Industries, Inc.Approved
Caverject
VViatris Specialty LLC
Approved
Demadex
SSarfez Pharmaceuticals, Inc.
Approved
Betapace
LLegacy Health System
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Coumadin
AAbbott
Approved
Colcrys
Jazz PharmaceuticalsPhase 3
Pelacarsen
NovartisPhase 3
Cagrilintide
Novo NordiskPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes2 trials
Lip2 trials
Heart Failure2 trials
Vascular Function1 trial
Free Fatty Acids and Vascular Function in Subjects With Diabetes
Completed·—·Phase 1/2·NCT00153179·40 enrolled
10 more indications
Propranolol1 trial
Exercise1 trial
Mitochondria1 trial
Type 1 Diabetes1 trial
Metabolic Syndrome1 trial
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
Completed·—·Phase 2/3·NCT00759291·40 enrolled
Metabolism1 trial
Growth1 trial
Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia
Enrolling by invitation·—·Phase 2·NCT03338387·24 enrolled
Unspecified2 trials
Ketones, SGLT2, HFrEF
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT06229678·71 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for acipimox. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company